{
  "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
  "Country": "PO",
  "PICOs": [
    {
      "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "sotorasib",
      "Outcomes": "overall response rate (ORR), progression-free survival (PFS), overall survival (OS), disease control rate (DCR), quality of life"
    },
    {
      "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "docetaxel (DOC)",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
    },
    {
      "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "nintedanib in combination with docetaxel (NIN+DOC)",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
    },
    {
      "Population": "patients with NDRP with a KRAS G12C mutation who have experienced disease progression after at least one line of previous use",
      "Intervention": "Medicine X (under assessment)",
      "Comparator": "pemetrexed (PMX)",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), quality of life"
    }
  ],
  "ChunksUsed": 30,
  "ContextTokens": 6780
}